Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria
Open Access
- 26 August 2016
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 16 (1) , 1-8
Abstract
In order to evaluate the newly implemented gender-neutral HPV vaccination program, knowledge on the pre-vaccine prevalence of HPV infection is of paramount importance. Data on HPV infection among the women with no known previous cytological abnormalities are inexistent in Austria. This study presents data on the prevalence and distribution of HPV genotypes among women with no known cytological abnormalities in west Austria. Women between 18 and 65 years of age attending annual cervical cancer screening examinations were included in the study. Data on socio-demographic and reproductive factors were collected using structured questionnaires. Corresponding cervical swab samples were tested for the presence of HPV DNA and were genotyped. Questionnaire data and HPV status were linked with the corresponding cytological findings. A total of 542 women were included in the study. The mean age of the study participants was 35.9 (SD = 11.5). The prevalence of HPV infection was 20.5 %. HPV 16 (6.5 %), HPV 33 (3.3 %) and HPV 31 (3.0 %) were the dominant genotypes detected. Multivariate analysis showed that women younger than 30 years of age, smokers, women with a higher number of lifetime sexual partners and those living in the eastern districts of the study region were at significantly higher risk of HPV infection. With this study we present the first data on the prevalence of cervical HPV genotypes among a screening population in Austria. The results not only fill the missing information on HPV infection in this group of women in the country, they also provide baseline data for a future evaluation of the impact of the Austrian gender-neutral HPV immunization program. Moreover, our finding of higher HPV prevalence in the eastern compared to the western district of the study region may – at least partly – explain the east–west gradient in the standardized incidence rate of cervical cancer in the region.Keywords
Funding Information
- Tiroler Wissenschaftsfonds (to W.B.) (GZ:UNI-0404/1446).)
- MFF Tirol (262)
This publication has 27 references indexed in Scilit:
- The known unknowns of HPV natural historyJournal of Clinical Investigation, 2011
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyThe Lancet, 2011
- Prevalence of low‐risk and high‐risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: An epidemiological observational studyJournal of Medical Virology, 2010
- Epidemiologic risk profile of infection with different groups of human papillomavirusesJournal of Medical Virology, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Increased Risk of Oncogenic Human Papillomavirus Infections and Incident High-Grade Cervical Intraepithelial Neoplasia Among SmokersSexually Transmitted Diseases, 2009
- Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CINEuropean Journal of Epidemiology, 2007
- The epidemiology of genital human papillomavirus infectionVaccine, 2006
- Effects of cigarette smoke on the immune systemNature Reviews Immunology, 2002
- Signal-Amplified Colorimetric In Situ Hybridization for Assessment of Human Papillomavirus Infection in Cervical LesionsLaboratory Investigation, 2001